Newsletter Tool

PM Tracker

Today’s Big News

Mar 13, 2025

Mallinckrodt, Endo look to carve out brighter future through $6.7B merger

Eye surgery specialist BVI Medical claims $1B capital raise through owner TPG

George Church spinout GRObio explores strategic alternatives 6 months after Bayer-backed series B

‘I don't feel we lost momentum’: Takeda’s oncology execs sharpen focus after restructuring

Amid Vafseo's US launch, Akebia plots phase 3 study to grow CKD anemia med's reach

Featured

Mallinckrodt, Endo look to carve out brighter future through $6.7B merger

By Fraiser Kansteiner

Having spent the better part of the decade grappling with bankruptcy bids and opioid settlements, troubled drugmakers Mallinckrodt and Endo have decided to join forces to create a more flexible company and ultimately spin off their sizeable generics businesses.

Eye surgery specialist BVI Medical claims $1B capital raise through owner TPG

By Conor Hale

BVI said the move fully refinances its debt and adds new equity, both from TPG and additional new investors.

George Church spinout GRObio explores strategic alternatives 6 months after $60M series B

By Angus Liu

Synthetic biology specialist Gro Biosciences, born out of the George Church Lab at Harvard, is exploring strategic alternatives only about half a year after raising a series B backed by top venture capital funds, Fierce Biotech has learned.

‘I don't feel we lost momentum’: Takeda’s oncology execs sharpen focus after restructuring

By Gabrielle Masson

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the company’s focus on cell therapy to the backburner.

Amid Vafseo's US launch, Akebia plots phase 3 study to grow CKD anemia med's reach

By Fraiser Kansteiner

Following a hard-fought yet limited FDA approval last year, Akebia plans to kick off a phase 3 trial to assess its Vafseo as a potential treatment for anemia in late-stage CKD patients who aren’t on dialysis.

NFL drafts Novartis as league’s first corporate pharma partner

By Andrea Park

Novartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football league and a pharmaceutical company.

NIH allegedly cancels dozens of grants for vaccine hesitancy research: reports

By Darren Incorvaia

The National Institutes of Health is reportedly continuing its grant-canceling spree, now targeting dozens of research projects related to studying vaccine hesitancy and improving vaccine rates.

Zevra Therapeutics embarks on diagnosis push as Miplyffa launch gains steam

By Zoey Becker

Niemann-Pick disease type C therapy Miplyffa became commercially available in late November and by the year's end, a total of 109 prescription enrollment forms had been submitted. The company estimates there are around 900 patients with the disease in the U.S.

Samsung backs Alzheimer's blood test developer C2N Diagnostics with $10M

By Conor Hale

Samsung backed the Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial work and R&D pipeline.

Hologen AI commits up to $430M to help take MeiraGTx's Parkinson's gene therapy through phase 3 and beyond

By James Waldron

Artificial intelligence company Hologen AI has committed up to $430 million as part of a multifaceted agreement to help take MeiraGTx’s Parkinson’s disease gene therapy all the way to market.

Fierce podcasts

Don’t miss an episode

'The Top Line': A look at biotech's biggest money raisers of 2024

This week on "The Top Line," we dig into several of the biggest private funding rounds in biotech last year and discuss the shifting VC landscape.

'The Top Line': Research reveals ‘ticking DNA clock’ behind Huntington’s disease

Podnosis: Ways providers can simplify patient billing

Resources

Whitepaper

The Oncology Market: 2025 Outlook

Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Redefining vaccine trial recruitment

Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials.

Sponsored by: Avacare Clinical Research Network

Whitepaper